What are the management recommendations for a patient with an eGFR (estimated Glomerular Filtration Rate) of 61, indicating mild kidney impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 21, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of eGFR 61 mL/min/1.73 m²

An eGFR of 61 mL/min/1.73 m² represents CKD Stage 2 (mildly decreased kidney function) and requires annual monitoring with minimal medication adjustments at this level. 1

Classification and Current Status

  • Your eGFR of 61 mL/min/1.73 m² falls into CKD Stage 2 (60-89 mL/min/1.73 m²), defined as mildly decreased GFR with evidence of kidney damage 2, 1
  • This level of kidney function is considered mild renal insufficiency and does not yet meet criteria for moderate impairment (which begins at eGFR <60 mL/min/1.73 m²) 2

Monitoring Requirements

Annual assessments are sufficient at this eGFR level:

  • Measure serum creatinine and calculate eGFR once yearly 1
  • Obtain urine albumin-to-creatinine ratio (UACR) annually to assess for proteinuria 1
  • Check blood pressure at each clinical visit with target <130/80 mmHg 2, 1

Increase monitoring frequency to every 6 months if: 1

  • eGFR declines by >5 mL/min/1.73 m² per year
  • You have diabetes mellitus
  • Evidence of progressive kidney function decline emerges

Medication Management

At eGFR 61 mL/min/1.73 m², most medications require NO dose adjustment: 1

  • ACE inhibitors and ARBs can be used at standard doses with appropriate monitoring 2, 1, 3
  • Fenofibrate does not require dose reduction (adjustment only needed when eGFR <60 mL/min/1.73 m²) 1
  • Metformin can be continued safely at this eGFR level 4
  • Most other medications do not require adjustment until eGFR drops below 60 mL/min/1.73 m² 1, 5

Important monitoring for ACE inhibitors/ARBs: 3

  • Check serum creatinine and potassium within 7-14 days after starting or dose changes
  • Do not discontinue if creatinine increases ≤30% in absence of volume depletion
  • Monitor for hyperkalemia development

Prevention of Further Decline

Implement these strategies to slow progression:

  • Optimize blood pressure control to <130/80 mmHg, preferably with ACE inhibitors or ARBs if hypertension and albuminuria are present 2, 1
  • Achieve glycemic control if diabetic (target HbA1c ~7%) 2, 1
  • Avoid nephrotoxic medications including NSAIDs, which can worsen renal function and hypertension 2, 1, 6
  • Address cardiovascular risk factors including smoking cessation, weight management if obese, and regular physical activity 1

When to Escalate Care

Consider nephrology referral if: 1

  • Rapid eGFR decline (>5 mL/min/1.73 m² per year)
  • Significant proteinuria (UACR >300 mg/g)
  • Difficult-to-control hypertension despite multiple agents
  • Suspected non-diabetic kidney disease
  • eGFR declines to <60 mL/min/1.73 m² (entering Stage 3 CKD)

If eGFR drops below 60 mL/min/1.73 m²: 1

  • Increase monitoring frequency
  • Evaluate for CKD complications (anemia, bone disease, electrolyte abnormalities)
  • Begin more intensive medication dose adjustments 2, 5

Critical Pitfalls to Avoid

  • Do not assume "normal" creatinine means normal kidney function - elderly patients can have significantly reduced eGFR despite normal serum creatinine due to decreased muscle mass 6
  • Avoid NSAIDs as they can precipitate acute kidney injury and worsen hypertension, particularly problematic in elderly patients 2, 6
  • Do not combine ACE inhibitors with ARBs - dual RAAS blockade increases risks of hyperkalemia and acute kidney injury without additional benefit 2, 7
  • Temporarily hold ACE inhibitors/ARBs during serious intercurrent illness, volume depletion, before major surgery, or with IV contrast administration 3

References

Guideline

Management of Mildly Decreased Kidney Function

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Lisinopril Dosing and Monitoring in Renal Impairment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

How to adjust drug doses in chronic kidney disease.

Australian prescriber, 2019

Research

Drugs and the kidney.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.